source
- FDA to consider ‘innovative approaches’ to psychedelic drug developmentTop US Food and Drug Administration (FDA) officials said the agency is open to novel, “innovative approaches” to the clinical development of psychedelic drugs in light of the worsening mental healt…raps · 22h ago↗ source
- Novo Nordisk halts two IL-6 heart trials as Novartis suffers Phase 3 setbacks; Ionis wins first Alexander disease approvalNovo Nordisk announced it has ended two late‑stage studies of its investigational IL‑6 inhibitor ziltivekimab, which was being evaluated for cardiovascular disease. The decision follows an earlier…
- Evommune gives up hope for MRGPRX2 antagonist to treat itch after latest phase 2 fail